Formulary Group work programme


Forthcoming submissions 2015

This list is indicative and may be subject to change.

Adalimumab - SMC 1050/15 - Formulary Group advice will be published by 2nd June 2015. (Indication: for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy).

Anidulafungin - FG1 381/15 - Formulary Group advice will be published by 2nd June 2015. (Indication: invasive candidiasis in neutropenic adults).

Atomoxetine - SMC 909/13 - in progress. (Indication: treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme).

Azelastine hydrochloride + fluticasone propionate (Dymistaź) - SMC 921/13 - Formulary Group advice will be published by 2nd June 2015. (Indication: for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient).

Bosutinib - SMC 910/14 - Formulary Group advice will be published by 2nd June 2015. (Indication: treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options).

Budesonide - SMC 1043/15 - Formulary Group advice will be published by 2nd June 2015. (Indication: autoimmune hepatitis).

Dexamethasone - SMC 1046/15 - in progress. (Indication: treatment of adult patients with visual impairment due to diabetic macular oedema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy).

Entecavir - SMC 1049/15 -Formulary Group advice will be published 2nd June 2015. (Indication: treatment of chronic hepatitis B virus infection in nucleoside naive paediatric patients from 2 to <18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum alanine aminotransferase levels, or histological evidence of moderate to severe inflammation and/or fibrosis).

Idelalisib - SMC 1026/15 - Formulary Group advice will be published by 2nd June 2015. (Indication: in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy).

Idelalisib - SMC 1039/15 - Formulary Group advice will be published by 2nd June 2015. (Indication: monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment).

Indacaterol maleate plus glycopyrronium bromide - SMC 922/13 - in progress. (Indication: maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)).

Levonorgestrel - SMC 1036/15Formulary Group advice will be published by 2nd June 2015. (Indication: contraception for up to 3 years).

Linagliptin - SMC 850/13 - Formulary Group advice will be published by 2nd June 2015. (Indication: the treatment of type 2 diabetes mellitus to improve glycaemic control in adults in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control).

Liraglutide - SMC 1044/15 - Formulary Group advice will be published by 2nd June 2015. (Indication: for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with basal insulin when this, together with diet and exercise, does not provide adequate glycaemic control).

Nepafenac - SMC 813/12 - in progress. (Indication: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients).

Ofatumumab - SMC 1037/15 - Formulary Group advice will be published by 2nd June 2015. (Indication: ofatumumab in combination with chlorambucil or bendamustine is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy).

Ondanestron - SMC 912/13 - in progress. (Indication: in adults: prophylaxis and treatment of acute and delayed nausea and vomiting induced by chemotherapy, and radiotherapy. Prophylaxis and treatment of post-operative nausea and vomiting.
In paediatric populations: management of chemotherapy-induced nausea and vomiting in children aged ≥6 months and prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged ≥4 years).

Ponatinib - SMC 1032/15 -Formulary Group advice will be published by 2nd June 2015. (Indication: adult patients with
- chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation).

Ruxolitinib - SMC 867/13 - Formulary Group advice will be published by 2nd June 2015. (Indication: the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis).

Vedolizumab - SMC 1045/15 - Formulary Group advice will be published by 2nd June 2015. (Indication: the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END

« Previous: Formulary Group | Top | Next: Formulary Group decisions index »